Disposition and bioavailability of the β1-adrenoceptor antagonist talinolol in man-Reference-Cited by-同舟云学术

Disposition and bioavailability of the β1-adrenoceptor antagonist talinolol in man

Published:1995-07 Issue:5 Volume:16 Page:403-414
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Trausch Beate,Oertel R.,Richter K.,Gramatté T.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Reference30 articles.

1. The clinical importance of cardioselectivity and lipophilicity in beta blockers

2. Clinical pharmacology of β-adrenoceptor blocking drugs. In Betaxolol and other β-adrenoceptor Antagonists, Vol. 1, et al. (Eds), Raven, 1983, pp. 73–88.

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into Intestinal P-glycoprotein Function using Talinolol: A PBPK Modeling Approach;2023-11-22

2. Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup;Critical Care;2021-06-10

3. Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P‐Glycoprotein;The Journal of Clinical Pharmacology;2021-01-29

4. The effects of P-glycoprotein inhibitor zosuquidar on the sex and time-dependent pharmacokinetics of parenterally administered talinolol in mice;European Journal of Pharmaceutical Sciences;2021-01

5. Quantitative analysis of the effect of controlled-release formulation on nonlinear gastrointestinal absorption of P-glycoprotein substrate talinolol using physiologically based pharmacokinetic absorption model;Journal of Drug Delivery Science and Technology;2020-04